Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions
Table 2
Summary of TASC lesions, distribution of diseased vessels, and interventional characteristics.
TASC II classification
EVT group (n = 94)
Bypass group (n = 93)
value
Aortoiliac lesions
A
16 (17.0)
15 (16.3)
0.225
B
11 (11.7)
21 (22.8)
C
13 (13.8)
11 (12.0)
D
13 (13.8)
16 (17.4)
Femoropopliteal lesions
C
60 (63.8)
29 (31.2)
<0.001
D
34 (36.2)
64 (68.8)
Infrapopliteal lesions
B
40 (42.6)
42 (45.2)
0.238
C
40 (42.6)
30 (32.3)
D
14 (14.9)
21 (22.6)
Lesion length (cm)
18.5 ± 3.6 (15–29)
23.4 ± 5.2 (15–33.5)
<0.001
Number of distal runoffs
1.78 ± 0.72
1.96 ± 0.79
0.105
1 vessel
38 (40.4)
31 (33.3)
0.146
2 vessels
40 (42.6)
35 (37.6)
3 vessels
16 (17.0)
27 (29.0)
Stent implantation
94 (100)
0
BTK intervention
94 (100)
0
Bypass surgery
0
93 (100)
AK FPB
0
41 (44.1)
AK FPB plus tibial artery
0
17 (18.3)
BK FPB
0
23 (24.7)
BK FPB plus tibial artery
12 (12.9)
AK, above the knee; BK, below the knee; DPA, dorsalis pedis artery; EVT, endovascular therapy; FPB, femoropopliteal bypass; PTA, posterior tibial artery; TASC, intersociety consensus for the management of peripheral arterial disease.
